Chest
Volume 138, Issue 4, Supplement, October 2010, Page 840A
Slide PresentationsTuesday, November 2, 2010Safety and Efficacy of Bosentan in Combination With Sildenafil in PAH Patients Who Experience Inadequate Clinical Response to Monotherapy: The COMPASS-3 Study
Tuesday, November 2, 2010
Section snippets
Abstract
PURPOSE: Combination therapy may improve outcomes in patients with severe pulmonary arterial hypertension (PAH). However, the appropriate time and functional thresholds to initiate such an approach are ill-defined. COMPASS-3 assessed the benefits of a bosentan-based stepped approach utilizing a 6-minute walk distance (6MWD) threshold of 380m as the functional threshold.
METHODS: Treatment-naive PAH patients with a baseline (BL) 6MWD of 150-360m were enrolled. Patients received bosentan for 16
References (0)
Cited by (0)
Copyright © 2010 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.